Galectin Therapeutics (GALT) Insider Shlevin Buys $9.5K of Stock
Harold Shlevin purchased 7,732 shares of Galectin Therapeutics at $1.23 per share.
Reviewed by automated data checks against the source filing. How we make and check alerts
Harold Shlevin bought 7,732 shares of Galectin Therapeutics Inc. ($GALT) at an average price of $1.23, worth about $9,510.36, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $GALT is down 7.2% after 1 week, down 32.3% after 1 month and down 27.4% to date (from the $4.99 close on Jun 26, 2026).
GALT
Galectin Therapeutics Inc.
Key Points
- Harold Shlevin bought 7,732 shares of Galectin Therapeutics on June 26, 2026, at an average price of $1.23 per share, totaling $9,510.36.
- Shares of Galectin Therapeutics traded near $4.64 on Wednesday, with a market cap of $328.6 million and a 52-week high of $7.13.
- HC Wainwright & Co. reiterated a buy rating for Galectin Therapeutics with an $11 price target on June 23, 2026.
Get $GALT trade alerts by text
We text you when insiders, Congress or big funds trade $GALT. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Galectin Therapeutics Inc. alert may contain errors. Disclosures
Harold Shlevin, a key insider, has increased his stake in Galectin Therapeutics Inc. (NasdaqCM: GALT) by purchasing 7,732 shares. The transaction, completed on June 26, 2026, was at an average price of $1.23 per share, amounting to a total of $9,510.36.
Insider Buying and Selling at Galectin Therapeutics Inc.
In addition to Harold Shlevin's recent purchase, there was notable insider activity at Galectin Therapeutics. On June 29, 2026, Chief Medical Officer Jamil Khurram bought 47,467 shares at $2.50 each. On the same day, Shlevin sold 22,268 shares at $5.04 each under a planned transaction.
Galectin Therapeutics Inc. Stock Up 19.3%
Shares of Galectin Therapeutics traded near $4.64 on Wednesday. The company, with a market capitalization of about $328.6 million, operates in the biotechnology sector. Galectin's stock has a 52-week range between $2.03 and $7.13, with the 50-day moving average at $2.53 and the 200-day moving average at $3.72. The firm's beta is 0.494, indicating lower volatility compared to the broader market.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its buy rating for Galectin Therapeutics, setting a price target of $11. This target aligns with the consensus among analysts, who have a mean target price of $11 based on one analyst opinion.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for fibrotic diseases and cancer. The company's leading drug candidate, belapectin, is being tested in Phase 2 studies for patients with advanced fibrosis and cirrhosis. Headquartered in Norcross, Georgia, and led by CEO Joel Lewis, Galectin Therapeutics collaborates with SBH Sciences to develop additional therapies targeting galectin-3.
Bottom Line
Harold Shlevin's recent purchase of Galectin Therapeutics shares adds to the ongoing insider activity at the company. Investors often monitor such transactions for potential insights into insider confidence. However, it's crucial to remember that these insider trades reflect personal strategies and may not indicate future stock performance.
Related Filing Alerts
Source: Harold Shlevin's Form 4 filing on $GALT (Jun 26, 2026). Find the original filing: GALT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts